Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

(2016) Linda S. Steelman et al.   Aging-US

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

(2015) Ludovica Ciuffreda et al.   NEOPLASIA

Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment

(2013) Roland Nassim et al.   PLoS One

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

(2012) Elina Jokinen et al.   BMC CANCER

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

(2012) E J Haagensen et al.   BRITISH JOURNAL OF CANCER

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

(2012) Brett H. Simmons et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Stat3 Activation in Urothelial Stem Cells Leads to Direct Progression to Invasive Bladder Cancer

(2012) P. L. Ho et al.   CANCER RESEARCH

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

(2012) G. Migliardi et al.   CLINICAL CANCER RESEARCH

Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer

(2012) M. Sen et al.   CLINICAL CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas

(2012) E. Martin-Sanchez et al.   HAEMATOLOGICA

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer

(2012) Nuria Juanpere et al.   HUMAN PATHOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines

(2011) H Li et al.   Advances in Medical Sciences

Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer

(2011) Chen-Yun Yeh et al.   BMC CANCER

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer

(2011) A. L. Sabichi et al.   Cancer Prevention Research

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

(2011) K. P. Hoeflich et al.   CANCER RESEARCH

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

(2011) S. J. Shuttleworth et al.   CURRENT MEDICINAL CHEMISTRY

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

(2011) James A. McCubrey et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft

(2011) M. Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

(2011) K. M. Kinross et al.   MOLECULAR CANCER THERAPEUTICS

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

(2011) J. Yuan et al.   MOLECULAR CANCER THERAPEUTICS

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

(2011) M. Hidalgo et al.   MOLECULAR CANCER THERAPEUTICS

Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL

(2011) A E Sayan et al.   ONCOGENE

A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1

(2011) Gottfrid Sjödahl et al.   PLoS One

Update on Chemotherapy in the Treatment of Urothelial Carcinoma

(2011) Carrie Costantini et al.   TheScientificWorldJOURNAL

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers

(2010) Igor Makhlin et al.   BJU INTERNATIONAL

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

(2010) Jose J. Mansure et al.   CANCER BIOLOGY & THERAPY

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

(2010) Y. C. Henderson et al.   MOLECULAR CANCER THERAPEUTICS

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

Provider Treatment Intensity and Outcomes for Patients With Early-Stage Bladder Cancer

(2009) B. K. Hollenbeck et al.   JNCI-Journal of the National Cancer Institute

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

(2008) Stephen D. Barrett et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival

(2008) Chun-Liang Chen et al.   Molecular Cancer